The paper re-iterates the significant anti-fibrotic effect of Aramchol 300mg BID in patients with metabolic dysfunction associated steatohepatitis (MASH) Data is confirmed using 3 objective measurements; NASH CRN, paired ranked reading, and Artificial Intelligence (AI) quantitative digital analysis Continuous histological fibrosis scores generated in antifibrotic trials by digital pathology images analysis (DIA) quantify antifibrotic effects with greater sensitivity and larger dynamic range than Conventional Pathology TEL AVIV, Israel , Sept. 25, 2024 /PRNewswire/ -- Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals NASDAQ: GLMD, a little-known biotech stock, has become the center of attention as its shares have skyrocketed close to 400%. By 2 pm, the stock had traded over 80 million shares, a monumental leap from its average daily volume of just 75,000.
Galmed Pharmaceuticals (NASDAQ: GLMD ) stock is on the move Thursday after the company priced a public offering of its shares. Galmed Pharmaceuticals intends to offer up 6,578,947 shares of GLMD stock at a price of $2.28 per share.
Galmed Pharmaceuticals (NASDAQ: GLMD ) stock is gaining on Friday after the company announced an investment agreement with OnKai . That agreement has Galmed Pharmaceuticals making a $1.5 million equity investment in OnKai.